EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY 4.0

Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial

Andrew Sharp iD, Christine Cornforth, Richard Jackson, Jane Harrold, Mark A Turner, Louise C Kenny, Philip N Baker, Edward D Johnstone, Asma Khalil iD, Peter von Dadelszen iD, Aris T Papageorghiou, Zarko Alfirevic und 2 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 2024

DOI: 10.1111/1471-0528.17888 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2024. Verfasst von Andrew Sharp und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Sildenafil Citrate, Phosphodiesterase 5 Inhibitors, Fetal Growth Retardation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Severe early‐onset fetal growth restriction (FGR) causes stillbirth, neonatal death and neurodevelopmental impairment. Poor maternal spiral artery remodelling maintains vasoactive responsiveness but is susceptible to treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, which may improve perinatal outcomes.

Design

Superiority, double‐blind randomised controlled trial.

Setting

A total of 20 UK fetal medicine units. Population Pregnancies affected by FGR, defined as an abdominal circumference below the tenth centile with absent end‐diastolic flow in the umbilical artery between 22 +0 and 29 +6 weeks of gestation.

Methods

Treatment with sildenafil (25 mg three times/day) or placebo until delivery or 32 weeks of gestation. Main outcome measures All infants alive at hospital discharge were assessed for cardiovascular function and cognitive, speech/language and neuromotor impairment at 2 years of age. The primary outcome was survival without cerebral palsy or neurosensory impairment, or a Bayley‐III composite score of >85.

Results

In total, 135 women were randomised between November 2014 and July 2016 (70 to sildenafil and 65 to placebo). We previously published that there was no improvement in time to delivery or perinatal outcomes with sildenafil. In all, 75 babies (55.5%) were discharged alive, with 61 infants eligible for follow‐up (32 sildenafil and 29 placebo). One infant died (placebo), three mothers declined and ten mothers were uncontactable. There was no difference in neurodevelopment or blood pressure following treatment with sildenafil. Infants who received sildenafil had a larger head circumference at 2 years of age (median difference 49.2 cm, IQR 46.4–50.3, vs 47.2 cm, 95% CI 44.7–48.9 cm).

Conclusions

Sildenafil therapy did not prolong pregnancy or improve perinatal outcomes and did not improve infant neurodevelopment in FGR survivors. Therefore, sildenafil should not be prescribed for this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sildenafil CitratePhosphodiesterase 5 InhibitorsFetal Growth RetardationHumansFemalePregnancyDouble-Blind MethodChild, PreschoolNeurodevelopmental DisordersInfant, NewbornAdultTreatment OutcomeMaleInfantChild Development

Stichwörter der Autor:innen

birthweightfetal growth restrictioninfantneurodevelopmentnewbornplacentapregnancysildenafil citrate

Substanzen

Sildenafil CitratePhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
  • Liverpool Women's Hospital NHS Foundation Trust, Liverpool, UK.
  • Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.
  • College of Life Sciences, University of Leicester, Leicester, UK.
  • Faculty of Medicine Biology and Health, Maternal and Fetal Health Research Centre, School of Medical Sciences, University of Manchester, Manchester, UK.
  • Fetal Medicine Unit, St George's Hospital, University of London, London, UK.

ORCID-Profile: Andrew Sharp, Asma Khalil, Peter von Dadelszen

Förderung

  • National Institute for Health Research and Medical Research Council

Zitieren

APA

Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., Baker, P. N., Johnstone, E. D., Khalil, A., von Dadelszen, P., Papageorghiou, A. T., Alfirevic, Z., Vollmer, B., & STRIDER group (2024). Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17888

Vancouver

Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2024. doi:10.1111/1471-0528.17888

BibTeX
@article{Sharp2024,
  author = {Sharp, Andrew and Cornforth, Christine and Jackson, Richard and Harrold, Jane and Turner, Mark A and Kenny, Louise C and Baker, Philip N and Johnstone, Edward D and Khalil, Asma and von Dadelszen, Peter and Papageorghiou, Aris T and Alfirevic, Zarko and Vollmer, Brigitte and STRIDER group, STRIDER group},
  title = {Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2024},
  doi = {10.1111/1471-0528.17888}
}
Kostenlos starten →